Selected article for: "hazard ratio and significant hazard ratio"
Author: Thompson, M. A.; Henderson, J. P.; Shah, P. K.; Rubinstein, S. M.; Joyner, M. J.; Choueiri, T. K.; Flora, D. B.; Griffiths, E. A.; Gulati, A. P.; Hwang, C.; Koshkin, V. S.; Papadopoulos, E. B.; Robilotti, E. V.; Su, C. T.; Wulff-Burchfield, E. M.; Xie, Z.; Yu, P. P.; Mishra, S.; Senefeld, J. W.; Shah, D. P.; Warner, J. L.; Consortium, COVID-19 and Cancer
Title: Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19
  • Cord-id: zkvqjp1z
  • Document date: 2021_2_5
    • ID: zkvqjp1z
    Snippet: Convalescent plasma may benefit immunocompromised individuals with COVID-19, including those with hematologic malignancy. We evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic malignancy and COVID-19 from a multi-institutional cohort. 143 treated patients were compared to 823 untreated controls. After adjustment for potential confounding factors, convalescent plasma treatment was associated with improved 30-day mortality (haza
    Document: Convalescent plasma may benefit immunocompromised individuals with COVID-19, including those with hematologic malignancy. We evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic malignancy and COVID-19 from a multi-institutional cohort. 143 treated patients were compared to 823 untreated controls. After adjustment for potential confounding factors, convalescent plasma treatment was associated with improved 30-day mortality (hazard ratio, 0.60; 95% CI, 0.37-0.97). This association remained significant after propensity-score matching (hazard ratio, 0.52; 95% CI, 0.29-0.92). These findings suggest a potential survival benefit in the administration of convalescent plasma to patients with hematologic malignancy and COVID-19.

    Search related documents:
    Co phrase search for related documents
    • absolute lymphocyte count and acute respiratory infection: 1, 2, 3
    • absolute lymphocyte count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • absolute lymphocyte count and lymphocytic leukemia: 1, 2, 3
    • absolute lymphocyte count and lymphopenia common: 1, 2, 3
    • active treatment and acute respiratory infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active treatment and administration timing: 1, 2, 3
    • active treatment and low proportion: 1
    • active treatment and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active treatment and lymphocytic leukemia: 1, 2, 3, 4, 5, 6, 7, 8
    • active treatment and lymphoid malignancy: 1
    • active treatment and lymphopenia common: 1
    • acute respiratory infection and administration timing: 1, 2, 3, 4
    • acute respiratory infection and low proportion: 1, 2
    • acute respiratory infection and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
    • acute respiratory infection and lymphocytic leukemia: 1, 2, 3, 4, 5, 6
    • acute respiratory infection and lymphopenia common: 1, 2, 3
    • administration timing and lymphocyte count: 1
    • low proportion and lymphocyte count: 1, 2, 3, 4